Safety, PK and Efficacy of ONC‐392 (anti‐CTLA4 mAb) in Monotherapy and in Combination of Anti‐PD‐1 in Advanced Solid Tumors and NSCLC (PRESERVE‐001). Here, CTLA4 is linked to non-small cell lung carcinoma.